Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
Kamal Abu Jabal, Hila Ben-Amram, Karine Beiruti, Yunis Batheesh, Christian Sussan, Salman Zarka, Michael Edelstein, Kamal Abu Jabal, Hila Ben-Amram, Karine Beiruti, Yunis Batheesh, Christian Sussan, Salman Zarka, Michael Edelstein
Abstract
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
Keywords: COVID-19; Israel; immunogenicity; vaccine.
Conflict of interest statement
Conflict of interest: None declared.
Figures
References
- World Health Organization (WHO). WHO Coronavirus Disease (COVID-19) Dashboard. Geneva: WHO. [Accessed: 25 Jan 2021]. Available from:
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. 10.1056/NEJMoa2035389
- Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15. 10.1056/NEJMoa2034577
- Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-93. 10.1016/S0140-6736(20)32466-1
- Aldridge RW, Lewer D, Katikireddi SV, Mathur R, Pathak N, Burns R, et al. Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data. Wellcome Open Res. 2020;5:88. 10.12688/wellcomeopenres.15922.2
- Izurieta HS, Graham DJ, Jiao Y, Hu M, Lu Y, Wu Y, et al. Natural history of COVID-19: Risk factors for hospitalizations and deaths among> 26 million US Medicare beneficiaries. J Infect Dis. 2020 Dec 16;jiaa767. doi: 10.1093/infdis/jiaa767. Online ahead of print.
- Ministry of Health of Israel. [Coronavirus in Israel – general situation]. Jerusalem: Ministry of Health. [Accessed: 25 Jan 2021]. Hebrew. Available from:
- Turbett SE, Anahtar M, Dighe AS, Garcia Beltran W, Miller T, Scott H, et al. Evaluation of Three Commercial SARS-CoV-2 Serologic Assays and Their Performance in Two-Test Algorithms. J Clin Microbiol. 2020;59(1):59. 10.1128/JCM.01892-20
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-93. 10.1038/s41586-020-2639-4
- Lumley SF, Wei J, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021;2021(Jan):6.
- Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2020;2020.11.03.367391.
- Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 2 infection rates than antibody negative healthcare workers? Large 3 multi-centre prospective cohort study (the SIREN study), England: 4 June to November 2020. medRxiv. 10.1101/2021.01.13.21249642
- Centers for Disease Control and Prevention (CDC). Frequently Asked Questions about COVID-19 Vaccination. Atlanta: CDC. [Accessed: 25 Jan 2021]. Available from:
Source: PubMed